Search for Clinical Trial Results

Poxviridae Infections - 25 Studies Found
Status | Study |
Completed |
Study Name: Evaluation of Take and Safety of a Smallpox Vaccine in Healthy Young Adults Condition:
Date: 2005-11-24 Interventions: Biological: Smallpox vaccine, LISTER strain, from chick embryo cells |
Recruiting |
Study Name: IMVAMUNE® Smallpox Vaccine in Adult Healthcare Personnel at Risk for Monkeypox in the Democratic Republic of the Congo Condition: Monkeypox Virus Infection Date: 2016-09-07 Interventions: Biological: IMVAMUNE® Two doses of attenuated live virus smallpox vaccine (IMVAMUNE®) administ |
Recruiting |
Study Name: Transcriptomics Signature of Anti Vaccinia Memory B Cells Condition: Healthy Date: 2015-09-21 |
Completed |
Study Name: A Trial to Assess the Safety, Tolerability, and Pharmacokinetics of the Anti-Orthopoxvirus Compound Tecovirimat Condition: Smallpox Date: 2015-06-01 Interventions:
|
Recruiting |
Study Name: VA-008 ACAM2000® Vaccination of Plasma Donors for the Production of VIGIV Condition: Smallpox Vaccine Adverse Reaction Date: 2015-05-06 Interventions: Biological: Vaccination with ACAM2000 In this study (VA-008), healthy adult male and female volunteers w |
Completed |
Study Name: VRC 208: Dose, Safety and Immunogenicity of a Recombinant Modified Vaccinia Virus Ankara Ebola Vaccine, VRC-EBOMVA079-00-VP (MVA-EbolaZ), Administered Alone or as a Boost to cAd3-Ebola Vaccines in Healthy Adults Condition: Healthy Adult Immune Responses to Vaccine Date: 2015-04-03 Interventions:
|
Completed |
Study Name: Safety and Tolerability of a Modified Vaccinia Ankara (MVA)-Based Vaccine Modified to Express Brachyury and T-cell Costimulatory Molecules (MVA-Brachyury-TRICOM) Condition:
Date: 2014-03-04 Interventions: Drug: Tecovirimat Oral tablet 600mg daily dose(three capsules, 200 mg/capsule) |
Active, not recruiting |
Study Name: A Non-inferiority Trial to Compare MVA-BN® Smallpox Vaccine to ACAM2000® Condition: 18-42 Year Old Healthy Vaccinia-naïve Subjects Date: 2013-07-26 Interventions:
|
Completed |
Study Name: Phase II Trial to Assess Safety and Immunogenicity of IMVAMUNE® Condition: Smallpox Date: 2013-04-04 Interventions: Biological: MVA Smallpox Vaccine Subjects receive two dose regimen of IMVAMUNE® (1x10^8 TCID50/0.5 |